Table 1 Study population and treatment group characteristics
|  | Home therapy pdC1-INH (n = 25) | Home therapy icatibant (n = 12) | Hospital therapy pdC1-INH (n = 19) | Overall (n = 56) |
|---|---|---|---|---|
Sex, n (%) | ||||
 Female | 14 (56.0) | 8 (66.7) | 12 (63.2) | 34 (60.7) |
 Male | 11 (44.0) | 4 (33.3) | 7 (36.8) | 22 (39.3) |
Age, yrs, mean, (±SD) | 33.0 (19.0) | 36.0 (11.5) | 39.5 (24.2) | 36 (19.6) |
Age | ||||
  ≥ 15 years, n (%) | 18 (72.0) | 12 (100.0) | 14 (73.7) | 44 (78.6) |
  < 15 years, n (%) | 7 (28.0) | 0 | 5 (26.3) | 12 (21.4) |
Age at diagnosis, yrs, mean, (±SD) | 20 (16.0) | 30 (12.0) | 26 (20.0) | 25 (17.0) |
Time since diagnosis, yrs, mean, (±SD) | 13.0 (8.0) | 6.0 (6.0) | 13.0 (12.0) | 11 (9.0) |
Disease severity score, mean, (range) | 7.3 (3–10) | 6.7 (4–9) | 6.6 (3–10) | 6.9 (3–10) |
Duration of home therapy, months, mean, (range) | 25.1 (6–60) | 32.7 (12–60) | - | - |
Receiving long-term prophylaxis, n (%) | 6 (24.0) | 2 (16.7) | 5 (26.3) | 13 (23.2) |